Clinical trial
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With…
NCT04995523 · AstraZeneca, Industry · Recruiting
Key facts
| NCT number | NCT04995523 |
|---|---|
| Title | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC |
| Official title | Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC |
| Acronym | ARTEMIDE-01 |
| Lead sponsor | AstraZeneca, Industry |
| Status | Recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | AZD2936 |
| Enrollment | 210 |
| Start date | Sep 14, 2021 |
| Primary completion | Aug 18, 2026 |
| Completion | Mar 16, 2028 |
| First posted | Aug 9, 2021 |
| Last update posted | Nov 24, 2025 |
| Countries | Australia, Belgium, Brazil, China, Denmark, France, Georgia, Japan, Malaysia, Moldova, Netherlands, Singapore and 6 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: